[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356129-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356129-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","current-and-future-therapies-for-triple-negative-breast-cancer","Current and future therapies for triple-negative breast cancer","","Triple-negative breast cancer is an aggressive, biologically diverse subtype in which sustained disease control remains difficult despite an expanding treatment landscape. Existing reviews often classify TNBC therapies by drug type or molecular subtype, which can mask how response is shaped across interacting biological levels. This review integrates established and emerging strategies using a three-layer framework spanning tumor-cell intrinsic vulnerabilities, the local immune/stromal microenvironment, and host-level systemic modifiers, guiding precision therapy selection using evidence level, disease stage, biomarker reliability and patient tolerance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/current-and-future-therapies-for-triple-negative-breast-cancer/356129/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/current-and-future-therapies-for-triple-negative-breast-cancer/356129.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What framework does the review use to understand current and future TNBC therapies?","Question",{"text":63,"@type":64},"It applies a three-layer framework: tumor-cell intrinsic vulnerabilities, the local immune and stromal microenvironment, and host-level systemic modifiers. This structure links therapy response to interacting biological layers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is long-term disease control challenging in triple-negative breast cancer?",{"text":68,"@type":64},"TNBC remains aggressive and biologically heterogeneous, and the translation of targeted concepts has been uneven. Even with expanded therapeutic options, durable control is still clinically difficult in many settings.",{"name":70,"@type":61,"acceptedAnswer":71},"Which treatment approaches are summarized as established versus emerging in the review?",{"text":72,"@type":64},"Established strategies include chemotherapy, immune checkpoint blockade, antibody–drug conjugates, and PARP inhibition in biomarker-defined contexts. Emerging or exploratory strategies include pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death induction, cellular therapy, vaccines, microbiome-related interventions, liquid biopsy, AI-supported multiomics, and adaptive trial designs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356129,1791439833,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Wang et al. Journal of Hematology & Oncology (2026) 19:57 [https://doi.org/10.1186/s13045-026-01839-x](https://doi.org/10.1186/s13045-026-01839-x)  \nJournal of Hematology & Oncology  \nREVIEW Open Access  \nCurrent and future therapies for triplenegative breast cancer  \nZi-Xun Wang1,2†, Xi-Yu Liu 1,2†, Yu-Xiao Wu1,2†, Yu-Ling Xiao1,2†, Li-Ping Ge1,2, Song-Yang Wu1,2*†, Yi-Zhou Jiang1,2* and Zhi-Ming Shao1,2*  \nAbstract  \nTriple-negative breast cancer remains an aggressive and biologically heterogeneous breast cancer subtype. Although the therapeutic landscape has expanded, durable disease control remains clinically challenging in many settings. Existing reviews often organize TNBC therapy by drug class or molecular subtype, which can obscure how treatment response is shaped by interacting biological layers. Here, we review current and emerging therapeutic strategies through a three-layer framework: tumor-cell-intrinsic vulnerabilities, the local immune and stromal microenvironment, and host-level systemic modifiers. We summarize established approaches, including chemotherapy, immune checkpoint blockade, antibody–drug conjugates and PARP inhibition in biomarkerdefined settings, and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death induction, cellular therapy, vaccines, microbiome-related interventions, liquid biopsy, AI-supported multiomics and adaptive trial designs. This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy.  \nKeywords Triple-negative breast cancer, Tumor heterogeneity, Multilevel tumor biology, Integrative therapy, Precision oncology  \n†Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu, Yu-Ling Xiao and Song-Yang Wu contributed equally.  \n*Correspondence:  \nSong-Yang Wu [wusy19@fudan.edu.cn](wusy19@fudan.edu.cn)[ ](wusy19@fudan.edu.cn)Yi-Zhou Jiang [yizhoujiang@fudan.edu.cn](yizhoujiang@fudan.edu.cn)[ ](yizhoujiang@fudan.edu.cn)Zhi-Ming Shao [zhimingshao@fudan.edu.cn](zhimingshao@fudan.edu.cn)  \n1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China  \n2Department of Oncology, Shanghai Medical College, Fudan University Shanghai, Shanghai 200032, China  \nBackground  \nBreast cancer remains the most frequently diagnosed malignancy among women worldwide and continues to impose a substantial global burden. Mortality has declined over recent decades, but progress has slowed and incidence is rising among younger women [1–3].  \nTriple-negative breast cancer (TNBC) accounts for approximately 10 to 20% of breast cancers and is defined by the absence of ER, PR and HER2 amplification. This receptor profile limits endocrine therapy and traditional HER2-amplification-directed regimens, although HER2-low and HER2-ultralow ADCs are changing the internal stratification of HER2-negative breast cancer [4, 5].  \nTNBC also shows marked genomic, immune and microenvironmental heterogeneity, including frequent TP53 mutation, recurrent PIK3CA alteration,  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not pe","cbCaioHbNWzuAyU6","https://ap.wps.com/l/cbCaioHbNWzuAyU6","pdf",2970336,"English","# Background\n## Triple-negative breast cancer features and therapeutic implications\n# Three-layer biological framework\n## Tumor-cell intrinsic vulnerabilities\n## Immune and stromal tumor microenvironment\n## Host macroenvironment modifiers\n# Therapeutic strategies and selection logic\n## Established and biomarker-defined approaches\n## Emerging and exploratory strategies\n## Integrating evidence level, stage, biomarkers and patient tolerance","[{\"question\":\"What framework does the review use to understand current and future TNBC therapies?\",\"answer\":\"It applies a three-layer framework: tumor-cell intrinsic vulnerabilities, the local immune and stromal microenvironment, and host-level systemic modifiers. This structure links therapy response to interacting biological layers.\"},{\"question\":\"Why is long-term disease control challenging in triple-negative breast cancer?\",\"answer\":\"TNBC remains aggressive and biologically heterogeneous, and the translation of targeted concepts has been uneven. Even with expanded therapeutic options, durable control is still clinically difficult in many settings.\"},{\"question\":\"Which treatment approaches are summarized as established versus emerging in the review?\",\"answer\":\"Established strategies include chemotherapy, immune checkpoint blockade, antibody–drug conjugates, and PARP inhibition in biomarker-defined contexts. Emerging or exploratory strategies include pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death induction, cellular therapy, vaccines, microbiome-related interventions, liquid biopsy, AI-supported multiomics, and adaptive trial designs.\"}]","Current and future therapies for triple-negative breast cancer | PDF",1790123549,76,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bcc8551dbb44c325b4293c3d71e9e15.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acfb3ca9a6e3095012512d24fd445122.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c60f7284bc06637d47499be41d29cbf.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/036433eeea34323474be543547f3a50d.webp",980,1306]